Overview
- The Nature Biotechnology analysis, published in September 2026, found unanimous reductions in predicted biological age across six independent proteomic clocks in a 12-week randomized Phase IIa trial of rentosertib in idiopathic pulmonary fibrosis patients.
- The trial measured 2,841 serum proteins from 42 patients and recorded peak average age reductions of three to four years at Week 4 in the 30 mg twice-daily group, with some clocks showing reversals up to six years.
- Dosing produced divergent signals: the 30 mg twice-daily regimen gave the strongest age-reversal on proteomic clocks while the 60 mg once-daily dose produced the largest mean lung-function gain in forced vital capacity (+98.4 mL versus a −20.3 mL change on placebo).
- Mechanistic data show rentosertib is a TNIK inhibitor with senomorphic activity that downregulates senescence drivers (MMP10, MMP13, SPP1) and growth-factor pathways including RTK–PI3K and RAS–ERK.
- Insilico has advanced rentosertib into a Phase III trial in China, deposited the proteomic dataset at CNCB (OMIX008341) and open‑sourced analysis code on GitHub, but independent confirmation in larger, placebo-controlled studies is needed to prove clinical anti‑aging benefit.